Skip to main content
. 2022 Mar 17;139(11):1670–1683. doi: 10.1182/blood.2021013972

Table 2.

Adverse events

Grade 3-4 adverse events # (%) patients
Hematologic
 Anemia 1 (11)
 Lymphopenia 1 (11)
 Thrombocytopenia 1 (11)
 Hemolysis 1 (11)
Other
 Fever 2 (22)
 Vascular (hypertension) 2 (22)
 Gastrointestinal (elevated GGT, ALT or AST) 3 (33)

All grade 3 and 4 adverse events based on CTCAE v4.0 that were possibly, probably, or definitely related to study therapy are listed, along with the number (and percentage) of patients who experienced each toxicity. All patients enrolled were assessed for adverse events.